DRG Epidemiology's coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.
DRG Epidemiology's dysthymia forecast will answer the following questions:
Of all people with dysthymia, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with dysthymia, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dysthymia over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
In total, DRG Epidemiology forecasts one dysthymia patient populations, as follows:
Total 12-Month Prevalence of Dysthymia per 1,000 People Aged 15+ in 2021 and 2041ttttttttt
Relative Sizes of the Factors Contributing to the Trend in Total 12-Month Prevalent Cases of Dysthymia over the Next 20 Yearsttttttttt
12-Month Total Prevalent Cases
Studies Included in the Analysis of Dysthymia
Studies Excluded from the Analysis of Dysthymia
Risk/Protective Factors for Dysthymia
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.